The role of NK and NKT cells in the pathogenesis and improvement of multiple sclerosis following disease-modifying therapies.
immunotherapy
multiple sclerosis
natural killer cells
nature killer T cells
Journal
Health science reports
ISSN: 2398-8835
Titre abrégé: Health Sci Rep
Pays: United States
ID NLM: 101728855
Informations de publication
Date de publication:
Jan 2022
Jan 2022
Historique:
received:
19
02
2021
revised:
09
11
2021
accepted:
07
12
2021
entrez:
1
3
2022
pubmed:
2
3
2022
medline:
2
3
2022
Statut:
epublish
Résumé
Multiple sclerosis (MS) is an autoimmune inflammatory disease of the central nervous system (CNS) that T cells become autoreactive by recognizing CNS antigens. Both innate and adaptive immune systems are involved in the pathogenesis of MS. In recent years, the impact of innate immune cells on MS pathogenesis has received more attention. CD56 We aimed to evaluate the influence of MS therapeutic agents on NK and NKT cells and NK cell subtypes. The possible mechanism of each MS therapeutic agent has been presented here, focusing on the effects of different disease-modifying therapies on the number of NK and NKT subtypes. Expansion of CD56 Expansion of CD56
Sections du résumé
BACKGROUND
BACKGROUND
Multiple sclerosis (MS) is an autoimmune inflammatory disease of the central nervous system (CNS) that T cells become autoreactive by recognizing CNS antigens. Both innate and adaptive immune systems are involved in the pathogenesis of MS. In recent years, the impact of innate immune cells on MS pathogenesis has received more attention. CD56
AIM
OBJECTIVE
We aimed to evaluate the influence of MS therapeutic agents on NK and NKT cells and NK cell subtypes.
MATERIALS AND METHODS
METHODS
The possible mechanism of each MS therapeutic agent has been presented here, focusing on the effects of different disease-modifying therapies on the number of NK and NKT subtypes.
RESULTS
RESULTS
Expansion of CD56
CONCLUSION
CONCLUSIONS
Expansion of CD56
Identifiants
pubmed: 35229046
doi: 10.1002/hsr2.489
pii: HSR2489
pmc: PMC8865072
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
e489Informations de copyright
© 2022 The Authors. Health Science Reports published by Wiley Periodicals LLC.
Déclaration de conflit d'intérêts
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
Expert Rev Clin Pharmacol. 2014 Jan;7(1):9-19
pubmed: 24308792
PLoS One. 2013;8(3):e58438
pubmed: 23472197
J Exp Med. 2004 Apr 5;199(7):947-57
pubmed: 15051763
PLoS Biol. 2012 Feb;10(2):e1001255
pubmed: 22346732
J Neurol. 2020 Dec;267(12):3489-3498
pubmed: 31129710
J Neuroinflammation. 2016 May 20;13(1):113
pubmed: 27207486
J Neuroimmunol. 2008 Feb;194(1-2):62-9
pubmed: 18164423
Lancet Neurol. 2015 Feb;14(2):194-207
pubmed: 25772898
Int Immunol. 2003 Feb;15(2):279-88
pubmed: 12578858
Clin Immunol. 2011 Dec;141(3):348-56
pubmed: 21992960
Neurodegener Dis Manag. 2017 Oct;7(5):279-297
pubmed: 28849702
Neurol Neuroimmunol Neuroinflamm. 2015 Feb 12;2(3):e76
pubmed: 25738172
Mult Scler Relat Disord. 2017 Nov;18:29-32
pubmed: 29141817
Front Immunol. 2013 Mar 13;4:63
pubmed: 23493880
J Immunol. 2007 Dec 1;179(11):7415-23
pubmed: 18025185
Immunopharmacol Immunotoxicol. 2014 Apr;36(2):105-13
pubmed: 24601677
J Neuroimmunol. 2013 Oct 15;263(1-2):108-15
pubmed: 23920036
Mult Scler Relat Disord. 2018 Feb;20:25-27
pubmed: 29276998
J Exp Med. 2001 Dec 17;194(12):1801-11
pubmed: 11748281
Cell Death Differ. 2008 Feb;15(2):226-33
pubmed: 17541426
J Neuroimmunol. 2003 Jun;139(1-2):84-92
pubmed: 12799025
Immunology. 2015 Sep;146(1):1-10
pubmed: 26032048
PLoS Biol. 2005 Apr;3(4):e113
pubmed: 15799695
Expert Rev Neurother. 2018 Jun;18(6):515-522
pubmed: 29799288
Immunology. 1999 Dec;98(4):557-63
pubmed: 10594688
J Exp Med. 2005 Nov 7;202(9):1279-88
pubmed: 16275765
J Exp Med. 2002 Mar 4;195(5):625-36
pubmed: 11877485
Iran J Allergy Asthma Immunol. 2019 Apr 01;18(2):190-199
pubmed: 31066255
Cytometry A. 2018 Nov;93(11):1157-1164
pubmed: 30253046
J Immunol. 2013 Mar 1;190(5):1948-60
pubmed: 23345328
J Exp Med. 2002 Mar 4;195(5):637-41
pubmed: 11877486
J Immunol. 2010 Jul 15;185(2):1311-20
pubmed: 20543101
J Allergy Clin Immunol. 2013 Sep;132(3):536-544
pubmed: 23906377
Clin Exp Immunol. 2014 Jun;176(3):320-6
pubmed: 24387139
Front Immunol. 2019 Jul 19;10:1666
pubmed: 31379857
Annu Rev Immunol. 2007;25:297-336
pubmed: 17150027
Neurology. 2011 Apr 5;76(14):1214-21
pubmed: 21464424
Arch Neurol. 2009 Apr;66(4):483-9
pubmed: 19364933
Nat Genet. 2007 Aug;39(8):969-76
pubmed: 17643102
Proc Nutr Soc. 2012 Feb;71(1):62-6
pubmed: 21996367
Immunol Lett. 2019 Dec;216:63-69
pubmed: 31589897
Ann Neurol. 2004 Apr;55(4):458-68
pubmed: 15048884
J Neurol Neurosurg Psychiatry. 2019 May;90(5):514-521
pubmed: 30538138
Sci Rep. 2018 May 29;8(1):8194
pubmed: 29844361
Clin Immunol. 2010 Oct;137(1):41-50
pubmed: 20580616
J Immunol. 2000 Apr 15;164(8):4375-81
pubmed: 10754338
Lancet Neurol. 2010 Apr;9(4):381-90
pubmed: 20163990
Eur J Immunol. 1999 May;29(5):1667-75
pubmed: 10359121
Front Biosci (Landmark Ed). 2014 Jun 01;19(8):1240-50
pubmed: 24896348
Ann Clin Transl Neurol. 2015 May;2(5):445-55
pubmed: 26000318
Ann Anat. 1998 Aug;180(4):321-5
pubmed: 9728272
Brain. 2009 May;132(Pt 5):1175-89
pubmed: 19339255
J Neurol Sci. 2019 Mar 15;398:4-8
pubmed: 30658226
Ther Adv Neurol Disord. 2013 Nov;6(6):343-52
pubmed: 24228070
Mult Scler. 2004 Oct;10(5):494-8
pubmed: 15471363
J Clin Invest. 2004 Nov;114(10):1379-88
pubmed: 15545985
Front Immunol. 2018 Dec 04;9:2848
pubmed: 30564241
Clin Exp Immunol. 1982 Dec;50(3):495-502
pubmed: 7165996
Clin Exp Immunol. 2013 Sep;173(3):381-9
pubmed: 23611040
Mult Scler. 2019 Apr;25(4):510-512
pubmed: 30421641
Int Immunol. 2015 May;27(5):237-44
pubmed: 25574039
J Immunol. 2014 Aug 1;193(3):1035-46
pubmed: 24973441
J Pharmacol Exp Ther. 2007 Jun;321(3):1109-17
pubmed: 17351106
Mult Scler. 2016 Jul;22(8):1061-1070
pubmed: 26459150
Acta Neurol Scand. 1993 Jun;87(6):457-60
pubmed: 8356874
Mult Scler Relat Disord. 2019 Oct;35:239-240
pubmed: 31421627
Mult Scler. 2011 Dec;17(12):1441-8
pubmed: 21807759
J Neuroimmunol. 2010 Apr 15;221(1-2):7-14
pubmed: 19931190
CNS Neurosci Ther. 2018 Mar;24(3):193-201
pubmed: 29314605
Nat Rev Immunol. 2004 Mar;4(3):231-7
pubmed: 15039760
PLoS One. 2020 Feb 3;15(2):e0228380
pubmed: 32012202
Neurol Sci. 2007 Jun;28(3):121-6
pubmed: 17603762
Proc Natl Acad Sci U S A. 1993 Jul 15;90(14):6400-4
pubmed: 8341645
Immunology. 2007 Nov;122(3):409-17
pubmed: 17617156
J Neuroimmunol. 2011 Jun;235(1-2):70-6
pubmed: 21550672
PLoS One. 2013 Oct 04;8(10):e74664
pubmed: 24124453
J Neuroimmunol. 2019 Dec 15;337:577065
pubmed: 31526917
Eur J Immunol. 2018 Feb;48(2):380-383
pubmed: 29108094
Neurology. 1996 Oct;47(4):895-900
pubmed: 8857715
Eur J Immunol. 2001 Oct;31(10):3121-7
pubmed: 11592089
Mult Scler. 2019 Oct;25(12):1557-1559
pubmed: 31549941
Ann Neurol. 1985 Oct;18(4):439-42
pubmed: 2416266
J Neuroimmunol. 2011 Jul;236(1-2):111-7
pubmed: 21652010
Clin Exp Immunol. 2017 Sep;189(3):268-278
pubmed: 28498568
Proc Natl Acad Sci U S A. 2006 Apr 11;103(15):5941-6
pubmed: 16585503
Clin Exp Immunol. 2015 May;180(2):243-9
pubmed: 25565222
Front Immunol. 2018 May 07;9:834
pubmed: 29867923
Toxins (Basel). 2015 Nov 13;7(11):4730-44
pubmed: 26580651
Eur J Neurol. 2013 Jul;20(7):1032-42
pubmed: 23419064
PLoS One. 2012;7(6):e39625
pubmed: 22768101
J Neuroimmunol. 2009 Oct 30;215(1-2):125-8
pubmed: 19758707
J Neuroinflammation. 2019 Feb 26;16(1):49
pubmed: 30808363
J Neuroimmunol. 2006 Jul;176(1-2):134-40
pubmed: 16723156
J Neuroinflammation. 2008 Jul 31;5:32
pubmed: 18671877
Ann Anat. 2010 Aug 20;192(4):179-93
pubmed: 20692821
J Clin Apher. 1994;9(4):222-7
pubmed: 7538999
J Clin Invest. 2007 Aug;117(8):2302-12
pubmed: 17641782
Mult Scler. 1996 Nov;2(4):206-10
pubmed: 9345375